While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

New schizophrenia drug ‘could change the lives of millions of people’ - The US Food and Drug Administration has approved ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates. Shares of the company were down 2.5% in extended trading.

(Reuters) -Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not achieve ...